Revlimid

(lenalidomide)

ApprovedSmall molecule

KKaruna Therapeutics, Inc., a Bristol Myers Squibb company

Lenalidomide is used to treat certain types of cancer, including multiple myeloma (a blood cancer) and certain lymphomas, as well as a blood disorder called myelodysplastic syndrome where the bone marrow doesn't make enough healthy blood cells.[2] Revlimid is currently approved and in use across 118 indications[4].[1]

Revlimid is one of 1700 small molecule programs targeting Glioma. It is currently in Approved.

118

Indications

917

Total Trials

Active Trials

1,699

Competitors

FDA Application

NDA/BLA/ANDA regulatory filings

Patents

Pipeline

Status by Indication[4][1]

Indication

GliomaActive, not recruiting

CachexiaActive, not recruiting

HIV InfectionActive, not recruiting

Follicular Thyroid CarcinomaActive, not recruiting

Non-Hodgkins LymphomaActive, not recruiting

MetastasisApproved

PlasmacytomaActive, not recruiting

Prostate AdenocarcinomaApproved

Primary Systemic AmyloidosisActive, not recruiting

MacroglobulinemiaActive, not recruiting

GliomaPhase 1

Active, not recruiting

CachexiaPhase 1

Active, not recruiting

HIV InfectionPhase 2

Active, not recruiting

Follicular Thyroid CarcinomaPhase 2

Active, not recruiting

Non-Hodgkins LymphomaPhase 1

Active, not recruiting

MetastasisApproved

Approved

PlasmacytomaPhase 3

Active, not recruiting

Prostate AdenocarcinomaApproved

Approved

Primary Systemic AmyloidosisPhase 2

Active, not recruiting

MacroglobulinemiaPhase 2

Active, not recruiting

Showing 10 of 118 indications

Competition

Competitive Landscape

2828 competitors in Breast Cancer

#DrugCompanyPhaseTrials

Revlimid

KKaruna Therapeutics, Inc., a Bristol Myers Squibb company

Approved

1 2

Tecentriq

Roche

Preclinical

36 3

Adriamycin

GGynecologic Oncology Group

Preclinical

87 4

Avastin

BBio-Thera Solutions

Preclinical

153 5

Feraheme

AAzurity Pharmaceuticals

Preclinical

1 6

Sporanox

SSebela Pharmaceuticals Development LLC

Preclinical

1 7

Neoadjuvant Therapy

SSun Yat-sen University

Preclinical

3 8

Fentanyl Citrate

IINSYS Therapeutics Inc

Preclinical

2 9

Neoadjuvant Treatment

SShanghai Zhongshan Hospital

Preclinical

1 10

Perflutren Lipid Microsphere

IImaRx Therapeutics

Preclinical

Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.

Timeline

Expected Milestones

Q3 2026

Phase 2Active, not recruiting

Multiple Myeloma

NCT02253316

Q4 2026

Phase 2Active, not recruiting

Multiple Myeloma

NCT01816971

Phase 1/2Active, not recruiting

Non-Hodgkins Lymphoma

NCT04661007

Phase 1Active, not recruiting

Multiple Myeloma

NCT04091126

Phase 1/2Active, not recruiting

Lymphoma

NCT03015896

Q1 2027

Phase 2Not yet recruiting

Cognitive Impairment

NCT06177028

Clinical

Trials by Indication[1]

Multiple Myeloma77 trials

Upfront Chimeric Antigen Receptor T-Cell to Upgrade Response in Multiple Myeloma

Completed·MMedical College of Wisconsin·Phase 2·NCT05032820·40 enrolled

A Study to Compare the Efficacy and Safety of Idecabtagene Vicleucel With Lenalidomide Maintenance Therapy Versus Lenalidomide Maintenance Therapy Alone in Adult Participants With Newly Diagnosed Multiple Myeloma Who Have Suboptimal Response After Autologous Stem Cell Transplantation

Active, not recruiting· Bristol-Myers Squibb logo

Bristol-Myers Squibb·Phase 3·NCT06045806·79 enrolled

Phase II Study of Revlimid®, Oral Cyclophosphamide and Prednisone for Patients With Newly Diagnosed Multiple Myeloma

Completed·AAttaya Suvannasankha·Phase 2·NCT00540644·70 enrolled

Show 74 more trials

Combination of Revlimid, Melphalan and Dexamethasone as First Line Treatment for Multiple Myeloma

Terminated·NNYU Langone Health·Phase 2·NCT00843310·8 enrolled

S0833, Bortezomib, Thalidomide, Lenalidomide, Combination Chemotherapy, and Autologous Stem Cell Transplant in Treating Patients With Newly Diagnosed Multiple Myeloma

Withdrawn·SSWOG Cancer Research Network·Phase 2·NCT01055301

A Study of Atezolizumab (Anti-Programmed Death-Ligand 1 [PD-L1] Antibody) Alone or in Combination With an Immunomodulatory Drug and/or Daratumumab in Participants With Multiple Myeloma (MM)

Completed· Roche logo

Roche·Phase 1·NCT02431208·85 enrolled

Post-Autologous Transplant Maintenance With Isatuximab and Lenalidomide in Minimal Residual Disease Positive Multiple Myeloma

Recruiting·UUniversity of Illinois at Chicago·Phase 2·NCT05344833·50 enrolled

Study Comparing Carfilzomib, Lenalidomide, and Dexamethasone (CRd) vs Lenalidomide and Dexamethasone (Rd) in Subjects With Relapsed Multiple Myeloma

Completed· Amgen logo

Amgen·Phase 3·NCT01080391·792 enrolled

Study of Belantamab Mafodotin Plus Standard of Care (SoC) in Newly Diagnosed Multiple Myeloma

Active, not recruiting· GSK logo

GSK·Phase 1·NCT04091126·118 enrolled

VitD3 Supplementation in Patients With Multiple Myeloma

Recruiting·—·Phase 1·NCT05846880·100 enrolled

A Study of the Combination Vorinostat With Lenalidomide, Bortezomib and Dexamethasone for Patients With Newly Diagnosed Multiple Myeloma

Completed·EEmory University·Phase 1·NCT01038388·30 enrolled

Belantamab Mafodotin, Lenalidomide, and Daratumumab for the Treatment of Relapsed, Refractory, or Previously Untreated Multiple Myeloma

Terminated·MMayo Clinic·Phase 1·NCT04892264·5 enrolled

Phase II Study of IRD (Ixazomib, Lenalidomide, Dexamethasone) Post Autologous Stem Cell Transplantation Followed by Maintenance Ixazomib or Lenalidomide for Multiple Myeloma

Active, not recruiting·WWashington University School of Medicine·Phase 2·NCT02253316·236 enrolled

Phase II, Single-Center, Oral Panobinostat in Combination With Lenalidomide and Dexamethasone in Multiple Myeloma (MM)

Completed·AAjai Chari·Phase 2·NCT01651039·32 enrolled

Short Course Daratumumab in Patients With Multiple Myeloma

Completed·MMemorial Sloan Kettering Cancer Center·Phase 2·NCT03490344·10 enrolled

Study to Evaluate the Safety and Efficacy of Daratumumab and Carfilzomib-based Induction/Consolidation/Maintenance Therapy in Transplant-eligible, Ultra High-risk, Newly Diagnosed Multiple Myeloma

Recruiting·UUnion Hospital, Tongji Medical College, Huazhong University of Science and Technology·Phase 2·NCT06140966·54 enrolled

Isatuximab in Combination With Lenalidomide and Dexamethasone in High-risk Smoldering Multiple Myeloma

Active, not recruiting· Sanofi logo

Sanofi·Phase 3·NCT04270409·337 enrolled

Early Patient Access Single Named Patient Program for the Use of Ulocuplumab for the Treatment of Multiple Myeloma

No longer available·—··NCT02666209

Pre-transplant Purging and Post-transplant MRD-guided Maintenance Therapy With Elranatamab in Patients With High-risk Multiple Myeloma

Recruiting·MM.D. Anderson Cancer Center·Phase 2·NCT06207799·40 enrolled

To Evaluate Safety, Tolerability, and Clinical Activity of the Antibody-drug Conjugate, GSK2857916 Administered in Combination With Lenalidomide Plus Dexamethasone (Arm A), or in Combination With Bortezomib Plus Dexamethasone (Arm B) in Participants With Relapsed/Refractory Multiple Myeloma (RRMM)

Completed· GSK logo

GSK·Phase 1/2·NCT03544281·153 enrolled

Safety Study of Lenalidomide Maintenance Therapy Post Allogeneic HCT for High-risk Multiple Myeloma

Completed·CCenter for International Blood and Marrow Transplant Research·Phase 2·NCT00847639·30 enrolled

Delanzomib (CEP-18770) in Combination With Lenalidomide and Dexamethasone in Relapsed or Refractory Multiple Myeloma

Completed· Teva logo

Teva·Phase 1/2·NCT01348919·11 enrolled

A Study to Investigate the Safety and Clinical Activity of Belantamab Mafodotin in Combination With Daratumumab, Lenalidomide and Dexamethasone in Patients With Newly Diagnosed Multiple Myeloma Transplant Ineligible

Unknown status·HHellenic Society of Hematology·Phase 1/2·NCT05280275·36 enrolled

A Study of Linvo-VR vs DVRd in Transplant-Eligible Adult Participants With Newly Diagnosed Multiple Myeloma (NDMM)

Not yet recruiting· Regeneron logo

Regeneron·Phase 2/3·NCT07428369·1,570 enrolled

WT1 Vaccine Treatment of Patients With Multiple Myeloma After Autologous Stem Cell Transplantation

Completed·SSellas Life Sciences Group·Phase 1/2·NCT01827137·20 enrolled

Lenalidomide Intensification in Patients With Serologic/Asymptomatic Progression of Multiple Myeloma While on Lenalidomide Maintenance

Completed·MMemorial Sloan Kettering Cancer Center·Phase 2·NCT01463670·11 enrolled

Bispecific T-cell Redirectors as Part of First Line Treatment in Transplant Eligible Multiple Myeloma Patients

Recruiting·—·Phase 2·NCT06505369·50 enrolled

Study of the Efficacy and Safety of RsqVD Combination Therapy for Patients With Newly Diagnosed Multiple Myeloma

Completed·CCancer Trials Ireland·Phase 2·NCT02219178·42 enrolled

Vorinostat Plus Lenalidomide and Dexamethasone or Lenalidomide Plus Dexamethasone in Multiple Myeloma Patients Who Experience Biochemical Relapse During Lenalidomide Maintenance Therapy

Withdrawn·TTiziana Marangon·Phase 2·NCT01501370

Teclistamab-Daratumumab and Talquestamab-Daratumumab in Newly Diagnosed High-risk Multiple Myeloma

Active, not recruiting·PPETHEMA Foundation·Phase 2·NCT05849610·30 enrolled

Safety And Efficacy Of Lenalidomide As Maintenance Therapy In Patients With Newly Diagnosed Multiple Myeloma Following A Tandem Autologous-Allogeneic Transplant

Completed·FFondazione EMN Italy Onlus·Phase 2·NCT01264315·53 enrolled

Study With Elranatamab Versus Lenalidomide in Patients With Newly Diagnosed Multiple Myeloma After Transplant

Active, not recruiting· Pfizer logo

Pfizer·Phase 3·NCT05317416·811 enrolled

Study of Elotuzumab in Combination With Lenalidomide and Dexamethasone in Subjects With Multiple Myeloma and Various Levels of Renal Function

Completed· Bristol-Myers Squibb logo

Bristol-Myers Squibb·Phase 1·NCT01393964·35 enrolled

Lenalidomide/Bortezomib/Dexamethasone for Multiple Myeloma (MM)

Completed·MMassachusetts General Hospital·Phase 2·NCT01782963·50 enrolled

Phase II Study of Subcutaneous (SC) Bortezomib, Lenalidomide and Dexamethasone for Relapsed and/or Refractory Multiple Myeloma; Followed by SC Bortezomib Maintenance

Withdrawn·NNational Cancer Institute (NCI)·Phase 2·NCT01647165

A Study of Ixazomib Plus Lenalidomide and Dexamethasone in Adult Japanese Participants With Relapsed and/or Refractory Multiple Myeloma

Completed· Takeda logo

Takeda·Phase 2·NCT02917941·34 enrolled

Low-Dose Azacitidine, Lenalidomide, and Low-Dose Dexamethasone in Relapsed or Refractory Multiple Myeloma

Completed·—·Phase 1/2·NCT01155583·45 enrolled

Lenalidomide or Observation in Treating Patients With Asymptomatic High-Risk Smoldering Multiple Myeloma

Active, not recruiting·NNational Cancer Institute (NCI)·Phase 3·NCT01169337·226 enrolled

A Study of Venetoclax Plus Lenalidomide and Dexamethasone for the Treatment of Newly Diagnosed t(11;14)-Positive Multiple Myeloma in Subjects Who Are Ineligible for High-Dose Therapy

Withdrawn· AbbVie logo

AbbVie·Phase 2·NCT03785184

A Study to Assess Change in Disease Activity and Adverse Events (AE)s in Adult Participants With Multiple Myeloma Receiving Etentamig (ABBV-383) as an Intravenous (IV) Infusion Alone or in Combination With Oral, IV, Subcutaneous Daratumumab; Lenalidomide; Dexamethasone; Carfilzomib

Recruiting· AbbVie logo

AbbVie·Phase 1/2·NCT06892522·440 enrolled

Dendritic Cell/Myeloma Fusion Vaccine for Multiple Myeloma (BMT CTN 1401)

Completed·NNational Heart, Lung, and Blood Institute (NHLBI)·Phase 2·NCT02728102·203 enrolled

Expression-linked and R-ISS-adapted Stratification for First Line Therapy in Multiple Myeloma Patients

Recruiting·—·Phase 2/3·NCT05665140·100 enrolled

A Study to Evaluate the Safety of bb2121 in Subjects With High Risk, Newly Diagnosed Multiple Myeloma (NDMM)

Completed· Bristol-Myers Squibb logo

Bristol-Myers Squibb·Phase 1·NCT04196491·13 enrolled

Study of Selinexor Plus DRd for Newly Diagnosed Multiple Myeloma

Active, not recruiting·UUS Oncology Research·Phase 2·NCT04782687·73 enrolled

Comparison of 25mg Versus 5 mg Lenalidomide as Maintenance Therapy in Patients With Multiple Myeloma

Completed·GGesellschaft fur Medizinische Innovation - Hamatologie und Onkologie mbH·Phase 3·NCT00891384·194 enrolled

Combination Therapy of Lenalidomide/Bortezomib/Dexamethasone and Panobinostat in Transplant Eligible New Diagnosed Multiple Myeloma (MM) Patients

Completed·MM.D. Anderson Cancer Center·Phase 1·NCT01440582·77 enrolled

A Dose Escalation Study of the Combination of Lenalidomide (Revlimid®), Dexamethasone and Cyclophosphamide in Patients Refractory or Relapsing From Stable Disease With Multiple Myeloma

Completed·KKing's College Hospital NHS Trust·Phase 1/2·NCT00915408·32 enrolled

A Study to Assess A Change in Disease Activity and Adverse Events of Intravenous Etentamig and Daratumumab (Etentamig+D) Compared to Daratumumab, Lenalidomide, and Dexamethasone (DRd) in Adult Participants With Newly Diagnosed Multiple Myeloma Not Eligible for Transplant

Recruiting· AbbVie logo

AbbVie·Phase 2/3·NCT07095452·660 enrolled

IXAZOMIB Plus Lenalidomide and Dexamethasone Versus Placebo Plus Lenalidomide and Dexamethasone in Adult Patients With Newly Diagnosed Multiple Myeloma

Completed· Takeda logo

Takeda·Phase 3·NCT01850524·705 enrolled

Study Comparing Daratumumab, Lenalidomide, and Dexamethasone With Lenalidomide and Dexamethasone in Participants With Previously Untreated Multiple Myeloma

Completed· Johnson & Johnson logo

Johnson & Johnson·Phase 3·NCT02252172·737 enrolled

PH III Study of Lenalidomide and Dexamethasone With or Without Elotuzumab to Treat Previously Untreated Multiple Myeloma (ELO 1 Substudy)

Terminated· Bristol-Myers Squibb logo

Bristol-Myers Squibb·Phase 3·NCT01891643·23 enrolled

Lenalidomide Melphalan and Prednisone Versus High Dose Melphalan in Newly Diagnosed Multiple Myeloma Patients

Completed·FFondazione EMN Italy Onlus·Phase 3·NCT00551928·402 enrolled

Lenalidomide, Bortezomib and Dexamethasone Induction Therapy With Either Intravenous or Subcutaneous Isatuximab in Patients With Newly Diagnosed Multiple Myeloma

Completed·UUniversity of Heidelberg Medical Center·Phase 3·NCT05804032·514 enrolled

A Study Comparing Daratumumab, Lenalidomide, and Dexamethasone With Lenalidomide and Dexamethasone in Relapsed or Refractory Multiple Myeloma

Completed· Johnson & Johnson logo

Johnson & Johnson·Phase 3·NCT02076009·569 enrolled

Combination Treatment Therapy Approaches for the Treatment of High-Risk Multiple Myeloma, REACH Trial

Active, not recruiting·MMayo Clinic·Phase 2·NCT05497804·17 enrolled

Bendamustine in Combination With Lenalidomide and Dexamethasone in Refractory or Relapsed Multiple Myeloma

Completed·RRobert Redner, MD·Phase 1·NCT01042704·29 enrolled

A Study in Relapsed and/or Refractory Multiple Myeloma Patients Treated With Ixazomib Plus Lenalidomide and Dexamethasone

Completed· Takeda logo

Takeda··NCT03433001·295 enrolled

Evaluation of the Safety and the Efficacy of Carfilzomib Combined With Cyclophosphamide and Dexamethasone (CCyd) or Lenalidomide and Dex (CRd) Followed by ASCT or 12 Cycles of Carf Combined With Dex and Len for Patients Eligible for ASCT With Newly Diagnosed Multiple Myeloma.

Active, not recruiting·MMario Boccadoro·Phase 2·NCT02203643·477 enrolled

Lenalidomide, Cyclophosphamide, and Dexamethasone in Treating Patients With Newly Diagnosed Multiple Myeloma

Completed·MMayo Clinic·Phase 2·NCT00478218·53 enrolled

Lenalidomide & Adriamycin & Dexamethasone (RAD) in Newly Diagnosed, Multiple Myeloma Patients

Completed·MMeletios A. Dimopoulos·Phase 2·NCT02471820·45 enrolled

Selinexor Treatment for Multiple Myeloma Patients Who Are Refractory to Lenalidomide-containing Therapy.

Unknown status·OOncotherapeutics·Phase 1·NCT04519476·22 enrolled

A Study of Pembrolizumab (MK-3475) in Combination With Standard of Care Treatments in Participants With Multiple Myeloma (MK-3475-023/KEYNOTE-023)

Terminated· Merck & Co. logo

Merck & Co.·Phase 1·NCT02036502·77 enrolled

TCR Genetically Engineered PBMC and PBSC After Melphalan Conditioning Regimen in Treating Participants With Relapsed and Refractory Multiple Myeloma

Withdrawn·JJonsson Comprehensive Cancer Center·Phase 1·NCT03506802

Lenalidomide, Dexamethasone, and Clarithromycin in Treating Patients Who Have Undergone Stem Cell Transplant for Multiple Myeloma

Completed·FFred Hutchinson Cancer Center·Phase 2·NCT00445692·32 enrolled

Carfilzomib, Lenalidomide, and Dexamethasone Before and After Stem Cell Transplant in Treating Patients With Newly Diagnosed Multiple Myeloma

Active, not recruiting·UUniversity of Chicago·Phase 2·NCT01816971·76 enrolled

Pembrolizumab Cyclophosphamide and Lenalidomide for Patients With Relapsed Multiple Myeloma

Withdrawn·UUniversity of Leeds·Phase 1/2·NCT03191981

A Study to Evaluate Subcutaneous Daratumumab in Combination With Standard Multiple Myeloma Treatment Regimens

Completed· Johnson & Johnson logo

Johnson & Johnson·Phase 2·NCT03412565·265 enrolled

Daratumumab-Based Therapy for the Treatment of Newly Diagnosed Multiple Myeloma With Kidney Failure

Terminated·EEmory University·Phase 2·NCT04352205·17 enrolled

Immunomodulatory Drugs (Lenalidomide With or Without Pomalidomide) in Combination With a Corticosteroid Drug (Dexamethasone) for the Treatment of Multiple Myeloma

Terminated·MMayo Clinic·Phase 2·NCT05288062·17 enrolled

Phase II Study of Dexamethasone, Thalidomide and Lenalidomide for Subjects With Relapsed or Refractory Multiple Myeloma

Terminated·WWeill Medical College of Cornell University·Phase 2·NCT00538824·5 enrolled

Pembrolizumab, Lenalidomide, and Dexamethasone in Treating Patients With Newly Diagnosed Multiple Myeloma Eligible for Stem Cell Transplant

Completed·MMayo Clinic·Phase 2·NCT02880228·11 enrolled

Bortezomib and Dexamethasone With or Without Lenalidomide in Treating Patients With Multiple Myeloma Previously Treated With Dexamethasone

Terminated·NNational Cancer Institute (NCI)·Phase 3·NCT00522392·48 enrolled

The Efficacy and Safety of Colchicine Combined With Conventional Therapy in Multiple Myeloma Patients

Unknown status·—·Phase 3·NCT05802992·30 enrolled

Study of ACY-1215 in Combination With Lenalidomide, and Dexamethasone in Multiple Myeloma

Completed· Bristol-Myers Squibb logo

Bristol-Myers Squibb·Phase 1·NCT01583283·38 enrolled

Filgrastim in Treating Patients With Bortezomib-, Carfilzomib-, or IMID-Refractory Multiple Myeloma

Terminated·WWashington University School of Medicine·Phase 1·NCT01537861·7 enrolled

Selinexor Plus VRd in High Risk Newly Diagnosed Multiple Myeloma

Recruiting·XXia Zhongjun·Phase 1/2·NCT05422027·42 enrolled

Alternating Ixazomib Citrate and Lenalidomide as Maintenance Therapy After Stem Cell Transplant in Treating Patients With Multiple Myeloma

Completed·FFred Hutchinson Cancer Center·Phase 2·NCT02619682·30 enrolled

Lymphoma17 trials

Combination Therapy With Carfilzomib, Romidepsin, Lenalidomide in Patients With Relapsed or Refractory B- and T-cell Lymphomas

Completed·MMemorial Sloan Kettering Cancer Center·Phase 1/2·NCT02341014·27 enrolled

Brentuximab Vedotin and Lenalidomide in Patients With Relapsed/ Refractory T-cell Lymphoma or Hodgkin Lymphoma

Completed·PPeter MacCallum Cancer Centre, Australia·Phase 1·NCT03302728·6 enrolled

Phase II of Lenalidomide After Salvage Therapy in R/R Non-Hodgkin T-cell Lymphoma

Unknown status·SSamsung Medical Center·Phase 2·NCT03730740·79 enrolled

Show 14 more trials

ALX148, Rituximab and Lenalidomide for the Treatment of Indolent and Aggressive B-cell Non-Hodgkin Lymphoma

Active, not recruiting·MM.D. Anderson Cancer Center·Phase 1/2·NCT05025800·47 enrolled

An Early Phase Study of Venetoclax, Lenalidomide, and Rituximab/Hyaluronidase in Slow-Growing Lymphomas That Have Come Back After Treatment or Have Not Responded to Treatment

Active, not recruiting·TThomas Jefferson University·Phase 1·NCT04447716·4 enrolled

Lenalidomide and Ibrutinib in Treating Patients With Relapsed or Refractory B-Cell Non-Hodgkin Lymphoma

Active, not recruiting·NNational Cancer Institute (NCI)·Phase 1·NCT01955499·39 enrolled

Lenalidomide in Relapsed or Refractory Classical Hodgkin Lymphoma

Completed·WWashington University School of Medicine·Phase 2·NCT00540007·80 enrolled

Intravitreal Methotrexate and R2(Rituximab & Lenalidomide) Regimen in Newly-diagnosed Primary Vitreoretinal Lymphoma

Unknown status·PPeking Union Medical College Hospital·Phase 2·NCT03746223·42 enrolled

A Study of Revlimid in the Treatment of Non-Hodgkin's Lymphoma

Completed· Bristol-Myers Squibb logo

Bristol-Myers Squibb·Phase 2·NCT00413036·217 enrolled

Brentuximab Vedotin and Lenalidomide in Treating Patients With Relapsed or Refractory T-Cell Lymphomas

Withdrawn·—·Phase 1·NCT03373305

Trial on Lenalidomide Given as Maintenance Therapy for Relapsed Diffuse Large B Cell Lymphoma

Completed·IIRCCS San Raffaele·Phase 2·NCT00799513·48 enrolled

Safety And Efficacy Of Lenalidomide In Patients With Relapsed Or Refractory Aggressive Non-Hodgkin's Lymphoma (NHL)

Completed· Bristol-Myers Squibb logo

Bristol-Myers Squibb·Phase 2·NCT00179660·50 enrolled

Brentuximab Vedotin and Lenalidomide in Treating Patients With Stage IB-IVB Relapsed or Refractory T-Cell Lymphoma

Completed·JJohn Reneau·Phase 2·NCT03409432·26 enrolled

Lenalidomide And Rituximab as Maintenance Therapy in Treating Patients With B-Cell Non-Hodgkin Lymphoma

Terminated·—·Phase 1·NCT01045928·5 enrolled

Lenalidomide Combined With Modified DA-EPOCH and Rituximab (EPOCH-R2) in Primary Effusion Lymphoma or KSHV-associated Large Cell Lymphoma

Active, not recruiting·NNational Cancer Institute (NCI)·Phase 1/2·NCT02911142·17 enrolled

Nivolumab and Lenalidomide in Treating Patients With Relapsed or Refractory Non-Hodgkin or Hodgkin Lymphoma

Active, not recruiting·—·Phase 1/2·NCT03015896·36 enrolled

Study of Lenalidomide and Ofatumumab for the Treatment of Relapsed or Refractory Non-Hodgkin's Lymphoma

Completed·UUniversity of Nebraska·Phase 1/2·NCT01060384·46 enrolled

Lenalidomide15 trials

Lenalidomide and Obinutuzumab for Previously Untreated CLL

Withdrawn·UUniversity of California, San Diego·Phase 2·NCT02371590

Elranatamab/Lenalidomide Consolidation and/or Elranatamab Maintenance Versus Standard of Care After D-VRd Induction in Transplant-eligible NDMM Patients

Recruiting·IIntergroupe Francophone du Myelome·Phase 3·NCT06918002·824 enrolled

Non-interventional Study of Lenalidomide in the Clinical Routine Treatment of TD Patients With IPSS Low or Int-1 MDS and Isolated Del(5q)

Completed· Bristol-Myers Squibb logo

Bristol-Myers Squibb··NCT02279654·389 enrolled

Show 12 more trials

Treatment of B-CLL With Autologous IL2 and CD40 Ligand-Expressing Tumor Cells + Lenalidomide

Terminated·—·Phase 1·NCT01604031·2 enrolled

Lenalidomide in Comb w/Rituximab for Pts w/CD5+/CD20+ Hem Malignancies Who Relapse/Progress After Rituximab

Completed·HH. Lee Moffitt Cancer Center and Research Institute·Phase 2·NCT00609869·29 enrolled

Allogeneic GM-CSF Vaccine and Lenalidomide in Treating Myeloma Patients With Near Complete Remission

Completed·SSidney Kimmel Comprehensive Cancer Center at Johns Hopkins·Phase 2·NCT01349569·19 enrolled

Lenalidomide With Gemcitabine in Treatment of Untreated Advanced Carcinoma of the Pancreas

Completed·SSCRI Development Innovations, LLC·Phase 2·NCT00837031·72 enrolled

Lenalidomide Plus ICE in the Treatment of Refractory and Relapsed DLBCL

Unknown status·RRuijin Hospital·Phase 2·NCT03367143·39 enrolled

S1803, Lenalidomide +/- Daratumumab/rHuPh20 as Post-ASCT Maintenance for MM w/MRD to Direct Therapy Duration

Active, not recruiting·SSWOG Cancer Research Network·Phase 3·NCT04071457·1,100 enrolled

Fludarabine/Rituximab Combined With Escalating Doses of Lenalidomide in Untreated CLL

Completed·AArbeitsgemeinschaft medikamentoese Tumortherapie·Phase 1/2·NCT01703364·12 enrolled

Study to Evaluatethe Bioavailability and Food Effect Lenalidomide as an Oral Suspension

Completed· Bristol-Myers Squibb logo

Bristol-Myers Squibb·Phase 1·NCT02521714·28 enrolled

Lenalidomide in Treating Young Patients With Recurrent, Progressive, or Refractory CNS Tumors

Completed·NNational Cancer Institute (NCI)·Phase 1·NCT00100880·45 enrolled

A Phase II Trial of Mosunetuzumab, Polatuzumab, Tafasitamab, and Lenalidomide in Patients With Relapsed B-cell NHL

Recruiting·MM.D. Anderson Cancer Center·Phase 2·NCT05615636·36 enrolled

Methotrexate, Tafasitamab, Lenalidomide and Rituximab in Patients With PCNSL

Recruiting·UUniversity of Cologne·Phase 2·NCT05583071·20 enrolled

LOC-R01 Study of Lenalidomide and Ibrutinib in Association With Rituximab-Methotrexate Procarbazine Vincristin (R-MPV)

Active, not recruiting·IInstitut Curie·Phase 1/2·NCT04446962·118 enrolled

Diffuse Large B-Cell Lymphoma9 trials

Rituximab and Pembrolizumab With or Without Lenalidomide in Treating Patients With Relapsed Follicular Lymphoma and Diffuse Large B-Cell Lymphoma

Active, not recruiting·MM.D. Anderson Cancer Center·Phase 2·NCT02446457·53 enrolled

A Study of Durvalumab in Combination With R-CHOP or Lenalidomide Plus R-CHOP in Previously Untreated High-Risk Diffuse Large B-Cell Lymphoma

Completed· Bristol-Myers Squibb logo

Bristol-Myers Squibb·Phase 2·NCT03003520·46 enrolled

Assessment of Survival and Autonomy With Rituximab Plus Chemotherapy or Rituximab Plus Lenalidomide for Elderly Patients With Relapsed Diffuse Large B-cell Lymphoma

Unknown status·—·Phase 2·NCT04113226·114 enrolled

Show 6 more trials

Study to Evaluate the Safety and Efficacy of Tafasitamab Plus Lenalidomide in Participants With Relapsed or Refractory Diffuse Large B-Cell Lymphoma (firmMIND)

Active, not recruiting· Incyte logo

Incyte·Phase 3·NCT05429268·82 enrolled

Mitoxantrone Hydrochloride Liposome Combined With Rituximab and Lenalidomide (M+R2) in Patients With Relapsed and Refractory Diffuse Large B-Cell Lymphoma

Unknown status·JJianfeng Zhou·Phase 2·NCT05575973·55 enrolled

Rituximab, Lenalidomide, Acalabrutinib, Tafasitamab Alone and With Combination Chemotherapy for the Treatment of Newly Diagnosed Non-germinal Center Diffuse Large B-Cell Lymphoma, Smart Stop Study

Active, not recruiting·MM.D. Anderson Cancer Center·Phase 2·NCT04978584·62 enrolled

A Study of Obinutuzumab, Polatuzumab Vedotin, and Lenalidomide in Relapsed or Refractory Follicular Lymphoma (FL) and Rituximab in Combination With Polatuzumab Vedotin and Lenalidomide in Relapsed or Refractory Diffuse Large B-Cell Lymphoma (DLBCL)

Completed· Roche logo

Roche·Phase 1/2·NCT02600897·114 enrolled

Ibrutinib and Lenalidomide With Dose Adjusted EPOCH-R in Subjects With Relapsed/Refractory Diffuse Large B-cell Lymphoma

Completed·PPharmacyclics LLC.·Phase 1/2·NCT02142049·35 enrolled

Ibrutinib in Combination With Lenalidomide and Rituximab in Participants With Relapsed or Refractory Diffuse Large B-Cell Lymphoma

Completed·PPharmacyclics LLC.·Phase 1/2·NCT02077166·138 enrolled

Chronic Lymphocytic Leukemia8 trials

Lenalidomide and Ofatumumab in Treating Participants With Previously Treated Chronic Lymphocytic Leukemia or Small Lymphocytic Lymphoma

Completed·MM.D. Anderson Cancer Center·Phase 2·NCT01002755·36 enrolled

Lenalidomide With or Without Rituximab in Treating Patients With Chronic Lymphocytic Leukemia or Small Lymphocytic Lymphoma Who Have Undergone Autologous or Syngeneic Stem Cell Transplant

Withdrawn·FFred Hutchinson Cancer Center·Phase 2·NCT00833534

Lenalidomide in Treating Patients With High-Risk Chronic Lymphocytic Leukemia

Withdrawn·NNational Cancer Institute (NCI)·Phase 2·NCT01271283

Show 5 more trials

Lenalidomide in Patients With Chronic Lymphocytic Leukemia Older Than 65 Years of Age

Completed·MMemorial Sloan Kettering Cancer Center·Phase 2·NCT01011894·26 enrolled

Lenalidomide as Chemoprevention in Treating Patients With High-Risk, Early-Stage B-Cell Chronic Lymphocytic Leukemia

Terminated·RRoswell Park Cancer Institute·N/A·NCT01649791·8 enrolled

Lenalidomide as Immune Adjuvant in Patient's With Chronic Lymphocytic Leukemia (CLL)

Terminated·MM.D. Anderson Cancer Center·Phase 2·NCT01924169·3 enrolled

Study of Lenalidomide to Evaluate Safety and Efficacy in Patients With Relapsed or Refractory Chronic Lymphocytic Leukemia

Completed· Bristol-Myers Squibb logo

Bristol-Myers Squibb·Phase 2·NCT00963105·104 enrolled

Nonmyeloablative Stem Cell Transplantation for Chronic Lymphocytic Leukemia (CLL)

Terminated·MM.D. Anderson Cancer Center·Phase 2·NCT00899431·39 enrolled

45 more indications

Mantle Cell Lymphoma7 trials

Dose Finding Study of Ibrutinib Plus Lenalidomide / Rituximab in Relapsed or Refractory Mantle Cell Lymphoma

Active, not recruiting·HHackensack Meridian Health·Phase 1·NCT02446236·27 enrolled

Obinutuzumab, Zanubrutinib, and Lenalidomide Followed Short-Cycle of Obinutuzumab and Cytarabine in Newly Diagnosed Mantle Cell Lymphoma

Recruiting·IInstitute of Hematology & Blood Diseases Hospital, China·Phase 2·NCT06504199·39 enrolled

Tafasitamab, Lenalidomide and Venetoclax for the Treatment of Relapsed or Refractory Mantle Cell Lymphoma

Recruiting·—·Phase 2·NCT05910801·100 enrolled

Show 4 more trials

A Trial of Ibrutinib, Lenalidomide and Rituximab for Patients With Relapsed/Refractory Mantle Cell Lymphoma

Completed·LLund University Hospital·Phase 2·NCT02460276·50 enrolled

A Study to Determine the Efficacy of Lenalidomide Versus Investigator's Choice in Patients With Relapsed or Refractory Mantle Cell Lymphoma (MCL)

Completed· Bristol-Myers Squibb logo

Bristol-Myers Squibb·Phase 2·NCT00875667·254 enrolled

Lenalidomide, Umbralisib, and Ublituximab for the Treatment of Relapsed or Refractory Indolent Non-Hodgkin Lymphoma or Mantle Cell Lymphoma

Withdrawn·YYazeed Sawalha·Phase 1·NCT04635683

Rituximab, Bendamustine Hydrochloride, and Bortezomib Followed by Rituximab and Lenalidomide in Treating Older Patients With Previously Untreated Mantle Cell Lymphoma

Active, not recruiting·EEastern Cooperative Oncology Group·Phase 2·NCT01415752·373 enrolled

Myelodysplastic Syndrome6 trials

Idarubicin + Cytarabine and Lenalidomide in Patients With Myelodysplastic Syndrome (MDS), Acute Myeloid Leukemia (AML)

Completed·HH. Lee Moffitt Cancer Center and Research Institute·Phase 1/2·NCT00831766·51 enrolled

Immunotherapy Using Lenalidomide + Bystander Vaccine in High Risk Myelodysplastic Syndrome (MDS)

Completed·HH. Lee Moffitt Cancer Center and Research Institute·Phase 1·NCT00840931·22 enrolled

Lenalidomide and Darbepoetin in Low-Intermediate Risk Myelodysplastic Syndrome (MDS)

Terminated·MM.D. Anderson Cancer Center·Phase 2·NCT01222195·1 enrolled

Show 3 more trials

Lenalidomide After Failure of Hypomethylating Agents in Myelodysplastic Syndrome

Unknown status·UUlsan University Hospital·Phase 2·NCT01673308·35 enrolled

A Study of the Efficacy and Safety of Lenalidomide Combined to Escalating Doses of Chemotherapy in Intermediate-2-or High Risk Myelodysplastic Syndrome (MDS) and Acute Myeloid Leukemia (AML) With Del 5q

Unknown status·GGroupe Francophone des Myelodysplasies·Phase 2·NCT00885508·85 enrolled

Study of REVLIMID (Lenalidomide) Versus Placebo in Patients With Low Risk Myelodysplastic Syndrome

Completed·—·Phase 3·NCT01243476·61 enrolled

Follicular Lymphoma4 trials

Epigenetic Modulation in Relapsed/Refractory Follicular Lymphoma and Marginal Zone Lymphoma

Terminated·—·Phase 2·NCT01121757·11 enrolled

A Study to Compare the Efficacy and Safety of Golcadomide in Combination With Rituximab (Golca + R) vs Investigator's Choice in Participants With Relapsed/Refractory Follicular Lymphoma Who Have Received at Least 1 Prior Line of Systemic Therapy (GOLSEEK-4)

Recruiting· Bristol-Myers Squibb logo

Bristol-Myers Squibb·Phase 3·NCT06911502·400 enrolled

Combined Rituximab and Lenalidomide Treatment for Untreated Patients With Follicular Lymphoma

Completed· Bristol-Myers Squibb logo

Bristol-Myers Squibb·Phase 3·NCT01476787·1,030 enrolled

Show 1 more trial

A Phase 3 Study to Assess Efficacy and Safety of Tafasitamab Plus Lenalidomide and Rituximab Compared to Placebo Plus Lenalidomide and Rituximab in Patients With Relapsed/Refractory (R/R) Follicular Lymphoma or Marginal Zone Lymphoma.

Active, not recruiting· Incyte logo

Incyte·Phase 3·NCT04680052·654 enrolled

Acute Myeloid Leukemia4 trials

A Study Being Conducted at Multiple Locations to Compare Safety and Efficacy of Three Different Regimens; (1) High-Dose Lenalidomide; (2) Lenalidomide + Azacitidine; or (3) Azacitidine in Subjects ≥ 65 Years With Newly-Diagnosed Acute Myeloid Leukemia

Completed· Bristol-Myers Squibb logo

Bristol-Myers Squibb·Phase 2·NCT01358734·88 enrolled

Lenalidomide in Older Patients With Acute Myeloid Leukemia Without Chromosome 5q Abnormalities

Completed·WWashington University School of Medicine·Phase 2·NCT00546897·48 enrolled

Lenalidomide, Cytarabine, and Idarubicin in Treating Patients With Acute Myeloid Leukemia

Completed·NNational Cancer Institute (NCI)·Phase 1·NCT01132586·61 enrolled

Show 1 more trial

Lenalidomide In Patients With Acute Myeloid Leukemia

Terminated·UUniversity of Ulm·Phase 1·NCT00839059·14 enrolled

Myelodysplastic Syndromes3 trials

Lenalidomide Versus Placebo in Myelodysplastic Syndromes With a Deletion 5q[31] Abnormality

Completed· Bristol-Myers Squibb logo

Bristol-Myers Squibb·Phase 3·NCT00179621·205 enrolled

Lenalidomide and Azacitidine in Treating Patients With Advanced Myelodysplastic Syndromes

Completed·—·Phase 1/2·NCT00352001·37 enrolled

Lenalidomide Safety/Efficacy in Myelodysplastic Syndromes (MDS) Associated With a Deletion (Del)(5q) Cytogenetic Abnormality

Completed· Bristol-Myers Squibb logo

Bristol-Myers Squibb·Phase 2·NCT00065156·148 enrolled

Newly Diagnosed3 trials

Selinexor With Alternating Bortezomib or Lenalidomide Plus Dexamethasone in TIE Newly Diagnosed MM Patients

Active, not recruiting·IIda Bruun Kristensen·Phase 2·NCT04717700·50 enrolled

A Phase III Trial on the Effect of Elotuzumab in VRD Induction /Consolidation and Lenalidomide Maintenance in Patients With Newly Diagnosed Myeloma

Completed·UUniversity of Heidelberg Medical Center·Phase 3·NCT02495922·564 enrolled

Study of Lenalidomide/Ixazomib/Dexamethasone/Daratumumab in Transplant-Ineligible Patients With Newly Diagnosed MM

Active, not recruiting·AAlliance Foundation Trials, LLC.·Phase 2·NCT04009109·79 enrolled

Efficacy and Safety3 trials

Efficacy and Safety of Lenalidomide for Treatment of Autistic Spectrum Disorders

Completed·SSutter Medical Foundation·Phase 2·NCT00996931·6 enrolled

Efficacy and Safety of Pola-RCHP-X vs Pola-RCHP in Untreated DLBCL

Recruiting·RRuijin Hospital·Phase 2·NCT06803693·152 enrolled

Efficacy and Safety of Lenalidomide Combined With Azacitidine vs Azacitidine in the Treatment of MDS-RS

Unknown status·PPeking Union Medical College Hospital·Phase 4·NCT06004765·138 enrolled

Dexamethasone2 trials

Lenalidomide, Rituximab, Gemcitabine, Oxaliplatin and Dexamethasone in Relapse and Refractory DLBCL

Unknown status·TThe First Affiliated Hospital with Nanjing Medical University·Phase 1·NCT03795571·12 enrolled

Ixazomib and Dexamethasone Versus Ixazomib, Dexamethasone and Lenalidomide, Randomized With NFKB2 Rearrangement

Completed·EEmory University·Phase 2·NCT02765854·70 enrolled

Maintenance Therapy2 trials

2015-12: A Study Exploring the Use of Early and Late Consolidation/Maintenance Therapy

Active, not recruiting·UUniversity of Arkansas·Phase 2·NCT03004287·50 enrolled

Zanubrutinib-based Maintenance Therapy of Newly Diagnosed DLBCL With Initial Remission

Not yet recruiting·RRuijin Hospital·Phase 2·NCT06669143·19 enrolled

Treatment2 trials

A Study to Desensitize Allergic Reactions to Treatments for Blood Disorders

Completed·UUniversity Health Network, Toronto·Phase 2·NCT03959358·10 enrolled

Genotype-guided Treatment in DLBCL

Recruiting·RRuijin Hospital·Phase 3·NCT05351346·1,100 enrolled

Prostate Cancer2 trials

Study of Lenalidomide and Docetaxel in Subjects With Androgen Independent Prostate Cancer

Completed·—·Phase 1·NCT01378091·64 enrolled

Study to Evaluate Safety and Effectiveness of Lenalidomide in Combination With Docetaxel and Prednisone for Patients With Castrate-Resistant Prostate Cancer

Completed· Bristol-Myers Squibb logo

Bristol-Myers Squibb·Phase 3·NCT00988208·1,059 enrolled

Leukemia2 trials

Cord Blood Natural Killer (NK) Cells in Leukemia/Lymphoma

Completed·MM.D. Anderson Cancer Center·Phase 1·NCT02280525·8 enrolled

A Phase I, Multicenter, Open-label, Dose-escalation Study to Assess the Safety of Lenalidomide in Patients With Advanced Adult T-cell Leukemia-lymphoma and Peripheral T-cell Lymphomaperipheral T-cell Lymphoma

Completed· Bristol-Myers Squibb logo

Bristol-Myers Squibb·Phase 1·NCT01169298·13 enrolled

Real-world Study1 trial

A Real-world Study of Obinutuzumab-based Therapy for Previously Untreated FL

Recruiting·RRuijin Hospital··NCT05899621·332 enrolled

Non-Hodgkins Lymphoma1 trial

To Assess the Safety and Tolerability of Tafasitamab Alone or in Combination With Other Drugs in Japanese Participants With Non-Hodgkins Lymphoma (NHL)

Active, not recruiting·IIncyte Biosciences Japan GK·Phase 1/2·NCT04661007·72 enrolled

Myelosuppression1 trial

A Study of Low Dose Lenalidomide and Dexamethasone in Relapsed/Refractory Myeloma in Patients at High Risk for Myelosuppression

Completed·PPeter MacCallum Cancer Centre, Australia·Phase 2·NCT00482261·150 enrolled

Dendritic Cell1 trial

Combination of Lenalidomide and Autologous Mature Dendritic Cells Pulsed With KRN7000 in Myeloma

Completed·YYale University·Phase 1·NCT00698776·6 enrolled

Cognitive impairment1 trial

MCLENA-2: A Phase II Clinical Trial for the Assessment of Lenalidomide in Patients With Mild Cognitive Impairment

Not yet recruiting·SSt. Joseph's Hospital and Medical Center, Phoenix·Phase 2·NCT06177028·45 enrolled

Radiculopathy1 trial

Study to Evaluate the Efficacy and Safety of Lenalidomide in the Treatment of Painful Lumbar Radiculopathy

Completed· Bristol-Myers Squibb logo

Bristol-Myers Squibb·Phase 2/3·NCT00120120·181 enrolled

Combination Therapy1 trial

Optimizing Reversal of HIV Latency With Combination Therapy

Unknown status·EErasmus Medical Center·Phase 1/2·NCT06240520·49 enrolled

AL amyloidosis1 trial

Frontline Lenalidomide for AL Amyloidosis Involving Myocardium

Completed·SSeoul National University Hospital·Phase 3·NCT04298372·2 enrolled

Clinical Trial1 trial

MCLENA-1: A Clinical Trial for the Assessment of Lenalidomide in Amnestic MCI Patients

Completed·SSt. Joseph's Hospital and Medical Center, Phoenix·Phase 2·NCT04032626·15 enrolled

Blood Cancer1 trial

A Study of Tazemetostat in Combination With Various Treatments in Participants With Blood Cancer.

Withdrawn·EEpizyme, Inc.·Phase 1/2·NCT05205252

Primary Systemic Amyloidosis1 trial

Lendexal in Patients With Primary Systemic Amyloidosis (AL) Newly Diagnosed

Completed·PPETHEMA Foundation·Phase 2·NCT01194791·30 enrolled

Minimal Residual Disease1 trial

First Autologous Transplant on Minimal Residual Disease Markers in Previously Untreated Myeloma Undergoing Initial Treatment With Velcade

Completed·VVanderbilt-Ingram Cancer Center·Phase 2·NCT01215344·36 enrolled

Hematopoietic Cell Transplantation1 trial

A Study of Carfilzomib, Lenalidomide, Dexamethasone and Daratumumab for Patients With Relapsed/Refractory Myeloma With Salvage Autologous Hematopoietic Cell Transplantation

Active, not recruiting·MMemorial Sloan Kettering Cancer Center·Phase 2·NCT03556332·41 enrolled

Amyloidosis1 trial

Lenalidomide in Combination With Melphalan and Dexamethasone in Newly-diagnosed Light-chain (AL)-Amyloidosis

Completed·NNantes University Hospital·Phase 1/2·NCT00621400·27 enrolled

Hepatocellular Cancer1 trial

Lenalidomide for Advanced Hepatocellular Cancer:A Phase II Trial

Completed·—·Phase 2·NCT00717756·41 enrolled

Hodgkins lymphoma1 trial

Lenalidomide Maintenance Therapy Post Autologous Transplant for Hodgkins Lymphoma

Completed·WWashington University School of Medicine·Phase 1·NCT01207921·28 enrolled

HIV infection1 trial

Lenalidomide in Kaposi Disease Associated With HIV Infection

Terminated·FFrench National Agency for Research on AIDS and Viral Hepatitis·Phase 2·NCT01282047·12 enrolled

Chemotherapy1 trial

Lenalidomide Plus Chemotherapy for AML

Completed·MMassachusetts General Hospital·Phase 1·NCT01681537·36 enrolled

Angioimmunoblastic T-Cell Lymphoma1 trial

Efficacy of a Treatment With CHOP and Lenalidomide in First Line in Angioimmunoblastic T-cell Lymphoma (AITL)

Completed·TThe Lymphoma Academic Research Organisation·Phase 2·NCT01553786·80 enrolled

Ovarian Cancer1 trial

A 2 Stage Trial of Lenalidomide (REV) in Asymptomatic Ovarian Cancer Patients With Increasing CA 125 in Late Relapse

Completed·AARCAGY/ GINECO GROUP·Phase 1/2·NCT01111903·67 enrolled

Colorectal Cancer1 trial

Lenalidomide and Cetuximab in Treating Patients With Advanced Colorectal Cancer or Head and Neck Cancer

Completed·NNational Cancer Institute (NCI)·Phase 1·NCT01254617·24 enrolled

Hepatitis B1 trial

Investigation of the Enhancement of Response to Hepatitis B Vaccine by Lenalidomide in Plasma Cell Dyscrasias

Completed·—·Phase 2·NCT02041325·38 enrolled

Breast Cancer1 trial

A Pilot Study to Investigate the Effect of Cytotoxic Therapy and/or Radiotherapy on Cancer Related Sleep Disturbances in CLL and Breast Cancer Patients Experiencing Fatigue

Completed·MM.D. Anderson Cancer Center·Phase 2·NCT00792077·6 enrolled

Systemic1 trial

Systemic Anti-Cancer Therapy Dose Modifications for Individuals With Duffy Null Phenotype

Not yet recruiting·—·Phase 1·NCT07341867·90 enrolled

Monoclonal Gammopathy1 trial

Study of Lenalidomide as a Treatment for Neuropathy Associated With Monoclonal Gammopathy of Undetermined Significance

Terminated·—·Phase 2·NCT00665652·8 enrolled

POEMS syndrome1 trial

Ixazomib Citrate, Lenalidomide, and Dexamethasone in Treating Patients With POEMS Syndrome

Completed·MMayo Clinic·Phase 1·NCT02921893·21 enrolled

Cancer1 trial

CC-5013 in Treating Patients With Cancer That Has Not Responded to Previous Therapy

Completed·NNational Institutes of Health Clinical Center (CC)·Phase 1·NCT00031941

Plasma Cell Leukemia1 trial

Daratumumab, Bortezomib, Dexamethasone, Pegylated Liposomal Doxorubicin Hydrochloride, and Lenalidomide in Treating Participants With Plasma Cell Leukemia

Withdrawn·—·Phase 1·NCT03591744

Advanced Solid Tumor1 trial

Valproic Acid-Based 2-Agent Oral Regimens for Patients With Advanced Solid Tumor

Completed·MM.D. Anderson Cancer Center·Phase 1·NCT00495872·204 enrolled

First-line Treatment1 trial

Real-world Study of Lenalidomide After First-line Treatment Lenvatinib With PD-1 in Advanced HCC

Completed·—·N/A·NCT07184424·24 enrolled

Efficacy1 trial

Efficacy of Pola-RCHP-X vs Pola-RCHP in Untreated DLBCL

Not yet recruiting·RRuijin Hospital·Phase 2·NCT06441097·152 enrolled

Older Patients1 trial

R-CHOP + R-HAD vs R-CHOP Followed by Maintenance Lenalidomide + Rituximab vs Rituximab for Older Patients With MCL

Completed·TThe Lymphoma Academic Research Organisation·Phase 3·NCT01865110·623 enrolled

Unspecified2 trials

GMMG-HD10 / DSMM-XX / 64007957MMY2003, MajesTEC-5

Recruiting·UUniversity of Heidelberg Medical Center·Phase 2·NCT05695508·160 enrolled

GEM-CLARIDEX: Ld vs BiRd

Unknown status·PPETHEMA Foundation·Phase 3·NCT02575144·286 enrolled

Regulatory

FDA Approval Timeline[5]

Dec 21, 2011

REVLIMID

NDA NDA021880

Sources

References

[1]
ClinicalTrials.gov — 917 trial records for lenalidomide. U.S. National Library of Medicine, National Institutes of Health.
[2]
MedlinePlus Drug Information — Revlimid drug information. U.S. National Library of Medicine, National Institutes of Health.
[3]
ChEMBL — lenalidomide compound record. European Bioinformatics Institute (EMBL-EBI).
[4]
Open Targets Platform — Drug–disease associations for lenalidomide. EMBL-EBI & Wellcome Sanger Institute.
[5]
OpenFDA — FDA approval records (NDA NDA021880). U.S. Food & Drug Administration.
[6]
FDA Orange Book — Patent and exclusivity data for Revlimid. U.S. Food & Drug Administration.
[7]
SEC EDGAR — Karuna Therapeutics, Inc., a Bristol Myers Squibb company company filings. U.S. Securities and Exchange Commission.

Details

Drug Info

Quick Facts

Mechanism of Action: CRL4(CRBN) E3 Ubiquitin Ligase Modulator; CRL4(CRBN) E3 Ubiquitin Ligase Inhibitor[3]
Modality: Small molecule[3]
Highest Phase: Approved[1]
Company: KKaruna Therapeutics, Inc., a Bristol Myers Squibb company

Patent Landscape[6]

Patent Cliff

Apr 27, 2027

Earliest patent expiration — generic entry possible after this date

Patent #Expires

7465800Apr 27, 2027

8741929Mar 8, 2028

Revlimid

Status by Indication[4][1]

Competitive Landscape

Expected Milestones

Q3 2026

Q4 2026

Q1 2027

Trials by Indication[1]

Multiple Myeloma77 trials

Lymphoma17 trials

Lenalidomide15 trials

Diffuse Large B-Cell Lymphoma9 trials

Chronic Lymphocytic Leukemia8 trials

Mantle Cell Lymphoma7 trials

Myelodysplastic Syndrome6 trials

Follicular Lymphoma4 trials

Acute Myeloid Leukemia4 trials

Myelodysplastic Syndromes3 trials

Newly Diagnosed3 trials

Efficacy and Safety3 trials

Dexamethasone2 trials

Maintenance Therapy2 trials

Treatment2 trials

Prostate Cancer2 trials

Leukemia2 trials

Real-world Study1 trial

Non-Hodgkins Lymphoma1 trial

Myelosuppression1 trial

Dendritic Cell1 trial

Cognitive impairment1 trial

Radiculopathy1 trial

Combination Therapy1 trial

AL amyloidosis1 trial

Clinical Trial1 trial

Blood Cancer1 trial

Primary Systemic Amyloidosis1 trial

Minimal Residual Disease1 trial

Hematopoietic Cell Transplantation1 trial

Amyloidosis1 trial

Hepatocellular Cancer1 trial

Hodgkins lymphoma1 trial

HIV infection1 trial

Chemotherapy1 trial

Angioimmunoblastic T-Cell Lymphoma1 trial

Ovarian Cancer1 trial

Colorectal Cancer1 trial

Hepatitis B1 trial

Breast Cancer1 trial

Systemic1 trial

Monoclonal Gammopathy1 trial

POEMS syndrome1 trial

Cancer1 trial

Plasma Cell Leukemia1 trial

Advanced Solid Tumor1 trial

First-line Treatment1 trial

Efficacy1 trial

Older Patients1 trial

Unspecified2 trials

FDA Approval Timeline[5]

References

Drug Info

Quick Facts

Patent Landscape[6]

Related News